Organoids in cancer research
J Drost, H Clevers - Nature Reviews Cancer, 2018 - nature.com
The recent advances in in vitro 3D culture technologies, such as organoids, have opened
new avenues for the development of novel, more physiological human cancer models. Such …
new avenues for the development of novel, more physiological human cancer models. Such …
Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment
AC Garrido-Castro, NU Lin, K Polyak - Cancer discovery, 2019 - AACR
Triple-negative breast cancer (TNBC) remains the most challenging breast cancer subtype
to treat. To date, therapies directed to specific molecular targets have rarely achieved …
to treat. To date, therapies directed to specific molecular targets have rarely achieved …
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
Background Poly (adenosine diphosphate–ribose) polymerase inhibitors target cancers with
defects in homologous recombination repair by synthetic lethality. New therapies are …
defects in homologous recombination repair by synthetic lethality. New therapies are …
Pan-cancer analysis of whole genomes
Nature, 2020 - nature.com
Cancer is driven by genetic change, and the advent of massively parallel sequencing has
enabled systematic documentation of this variation at the whole-genome scale,–. Here we …
enabled systematic documentation of this variation at the whole-genome scale,–. Here we …
Substitution mutational signatures in whole-genome–sequenced cancers in the UK population
Whole-genome sequencing (WGS) permits comprehensive cancer genome analyses,
revealing mutational signatures, imprints of DNA damage, and repair processes that have …
revealing mutational signatures, imprints of DNA damage, and repair processes that have …
State-of-the-art strategies for targeting the DNA damage response in cancer
Genomic instability is a key hallmark of cancer that arises owing to defects in the DNA
damage response (DDR) and/or increased replication stress. These alterations promote the …
damage response (DDR) and/or increased replication stress. These alterations promote the …
Molecular subtypes of pancreatic cancer
Cancers that appear morphologically similar often have dramatically different clinical
features, respond variably to therapy and have a range of outcomes. Compelling evidence …
features, respond variably to therapy and have a range of outcomes. Compelling evidence …
TBCRC 048: phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes
PURPOSE Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi), is approved
for the treatment of human epidermal growth factor receptor 2 (HER2)–negative metastatic …
for the treatment of human epidermal growth factor receptor 2 (HER2)–negative metastatic …
Clinical and translational advances in ovarian cancer therapy
Ovarian cancer is an aggressive disease that is frequently detected at advanced stages and
is initially very responsive to platinum-based chemotherapy. However, the majority of …
is initially very responsive to platinum-based chemotherapy. However, the majority of …
Mutational signatures: emerging concepts, caveats and clinical applications
Whole-genome sequencing has brought the cancer genomics community into new territory.
Thanks to the sheer power provided by the thousands of mutations present in each patient's …
Thanks to the sheer power provided by the thousands of mutations present in each patient's …